Fig 2: Enrichment plots from the gene set enrichment analysis (GSEA). (A–F) Several biological processes and pathways were differentially enriched in CHRDL1-related LUAD. NES, normalized ES; p.adj, adjusted P-value; FDR, false discovery rate.

Fig 3: Expression difference of CHRDL1 in normal samples and tumour samples. (A) Expression of CHRDL1 in normal samples from TCGA and GTEx and tumour sample of LUAD. (B) Expression levels of CHRDL1 in paired tumour and adjacent samples of LUAD. (C) ROC analysis of CHRDL1 expression showing promising discrimination power between tumor and non-tumor tissues in LUAD. (D) Expression levels of CHRDL1 in Pan-cancer. ns, P{greater than or equal to}0.05; *, P<0.05; **, P<0.01; ***, P<0.001.

Fig 4: Association between CHRDL1 expression and clinicopathologic characteristics, including (A–H): T stage (P<0.001), N stage (P=0.003), Pathologic stage (P=0.003), Tumor status (P=0.006), Primary therapy outcome (P=0.030), TP53 status (P<0.001), Gender (P<0.001) and Age (P<0.001) in patients with LUAD in a TCGA cohort.

Fig 5: Impact of CHRDL1 expression on OS (A), DSS (B) and DFS (C) in patients with LUAD in a TCGA cohort. The bottom half of the picture showed that the risk table records the number of people who were still following at each point in time.